Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 191

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 191
---
 of property, plant and equipment and software                                                             | -1,808 |  -1,677 |  -1,599 |
| Acquisitions of intangible assets, equity interests and other non-current financial assets(a)                          | -1,434 |  -1,091 |    -796 |
| Proceeds from disposals of property, plant and equipment, intangible assets and othernon-current assets, net of tax(a) |    805 |     789 |   1,382 |
| Repayments of lease liabilities(b)                                                                                     |   -282 |    -253 |    -280 |
| Other items(c)                                                                                                         |     67 |     370 |    -766 |
| Free cash flow (non-IFRS)                                                                                              |  5,955 |   7,409 |   7,579 |

(a) Free cash flow includes investments and divestments not exceeding a cap of €500 million per transaction. (b) Cash outflows relating to repayments of the principal portion of lease liabilities (IFRS 16) are included in free cash flow. (c) In 2022, includes an upfront payment of $900 million, a regulatory milestone payment of $100 million in connection with the one-time income from the Libtayo transaction further to the restructuring of the Immuno-Oncology collaboration agreement with Regeneron (see Note C.1. to our consolidated financial statements, included at Item 18. of this annual report). (d) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. B.2. Consolidated balance sheet and debt Total assets were € 132,798 million as of December 31, 2024 , compared with € 126,464 million as of December 31, 2023 , a increase of € 6,334 million. Total equity was € 77,857 million as of December 31, 2024 , versus € 74,353 million as of December 31, 2023 . The year-on-year net change reflects the following principal factors: • increases: our net income for 2024 (€ 5,618 million) and positive currency translation differences (€ 2,459 million); and • decreases: the dividend paid to our shareholders in respect of the 2023 financial year (€ 4,704 million) and repurchases